What is the recommended management for a patient with dilated cardiomyopathy and an absolute eosinophil count of 1500 cells/µL?

Management of Dilated Cardiomyopathy with Absolute Eosinophil Count of 1500 cells/µL

In a patient with dilated cardiomyopathy and an AEC of 1500 cells/µL, you must immediately investigate for eosinophilic myocarditis as the underlying cause and initiate corticosteroid therapy while completing diagnostic workup, as this represents a potentially reversible cause of cardiomyopathy with high mortality if untreated. 1

Diagnostic Approach

Confirm Hypereosinophilia

• Repeat the eosinophil count to confirm persistent elevation >1500 cells/µL 1
• The historical requirement of 6-month duration is no longer mandatory; greater emphasis is now placed on constellation of symptoms 1

Establish Cardiac Involvement

Endomyocardial biopsy remains the gold standard for diagnosing eosinophilic myocarditis, though sampling errors can yield false-negatives 1, 2. The biopsy should look for:

• Eosinophilic infiltration of myocardium
• Myocardial necrosis
• Focal fibrotic scarring

Cardiac MRI is highly valuable and should be performed to assess:

• Subendocardial edema (increased T2 signal)
• Late gadolinium enhancement in subendocardial pattern
• Apical thrombi
• Evidence of restrictive physiology 1, 3

Echocardiography will help identify:

• LV/RV apical obliteration
• Restrictive cardiomyopathy pattern
• Thrombus formation
• Degree of systolic dysfunction 1, 4

Identify Secondary Causes

This is critical before labeling as idiopathic hypereosinophilic syndrome. Evaluate for 1:

• Drug/vaccine hypersensitivity (most common reversible cause)
• Parasitic infections (especially in tropical/subtropical regions or travel history)
• Neoplastic processes (requires hematology consultation for specific analysis)
• Eosinophilic granulomatosis with polyangiitis (EGPA): Look for asthma, rhinosinusitis, peripheral neuropathy, ANCA positivity (30-40% are MPO-ANCA positive) 5, 6
• Other organ involvement: skin (69%), pulmonary (44%), gastrointestinal (38%) 1

Treatment Strategy

Immediate Management

Initiate corticosteroid therapy as primary treatment for eosinophilic myocarditis 1:

• Prednisone 1 mg/kg/day for 4 weeks, then taper to 0.33 mg/kg/day for 5 months 7
• This regimen has demonstrated improvement in LV function from 30% to 45% ejection fraction 7
• In severe cases with massive infiltration, doses up to 1.5 mg/kg/day have been used successfully 8

Important caveat: While corticosteroids are considered primary therapy, the evidence supporting their efficacy is not robust from randomized trials 1. However, case series show dramatic clinical improvement with normalization of eosinophil counts and recovery of LV function 8.

Adjunctive Immunosuppression

Add azathioprine 2 mg/kg/day for 6 months in virus-negative eosinophilic inflammatory cardiomyopathy 7. This combination has shown:

• Resolution of heart failure symptoms to NYHA class II
• Improvement in ejection fraction
• Sustained clinical stability

Standard Heart Failure Management

Implement guideline-directed medical therapy for heart failure with reduced ejection fraction concurrently 1:

• ACE inhibitors/ARBs
• Beta-blockers
• Mineralocorticoid receptor antagonists
• Diuretics for volume management
• SGLT2 inhibitors (based on contemporary HF guidelines)

Disease Stage-Specific Considerations

Eosinophilic myocarditis progresses through three stages 1:

1. Necrotic stage: Myocardial necrosis, often subclinical but can present as fulminant myocarditis
2. Thrombotic stage: High risk of thromboembolism from mural thrombi
3. Fibrotic stage: Irreversible restrictive cardiomyopathy (Löffler endocarditis)

Anticoagulation is essential during the thrombotic stage due to high thromboembolic risk 1, 3. Consider therapeutic anticoagulation if:

• Thrombi identified on imaging
• Severe LV dysfunction where thrombus cannot be excluded
• Evidence of thrombotic stage disease

Multidisciplinary Consultation

Hematology consultation is warranted for specific analysis to guide treatment, particularly to:

• Exclude myeloproliferative disorders
• Identify clonal eosinophilia
• Guide targeted therapy if specific mutations identified 1

Consider rheumatology consultation if EGPA is suspected based on asthma, rhinosinusitis, or ANCA positivity 6

Monitoring and Follow-up

• Serial eosinophil counts to assess treatment response
• Repeat echocardiography at 3-6 months to evaluate LV function recovery
• Cardiac MRI can track response to therapy 1
• Monitor for steroid-related complications during prolonged therapy

Advanced Therapies

If the patient fails to respond to immunosuppression or presents with:

• Fulminant myocarditis requiring mechanical support
• Progressive deterioration despite optimal therapy
• Advanced heart failure

Consider 1, 9, 2:

• Mechanical circulatory support (ECMO, intra-aortic balloon pump) as bridge
• Cardiac transplantation for end-stage disease refractory to medical management
• Transplant pathology can provide definitive diagnosis if biopsy was non-diagnostic 2

Critical Pitfalls to Avoid

• Do not delay corticosteroids while awaiting biopsy results if clinical suspicion is high—eosinophilic myocarditis is the number one cause of morbidity and mortality in hypereosinophilic syndrome despite being the primary manifestation only 5% of the time 1
• Do not miss secondary causes, particularly drug hypersensitivity—removing the offending agent is curative
• Do not underestimate thromboembolic risk—anticoagulation may be life-saving
• False-negative biopsies occur—do not exclude diagnosis based solely on negative biopsy if clinical picture is consistent 2
• Peripheral eosinophilia may be absent in some cases of eosinophilic heart disease—tissue diagnosis becomes essential 10